Inventiva (NASDAQ:IVA) Price Target Increased to $20.00 by Analysts at Canaccord Genuity Group

Inventiva (NASDAQ:IVA) had its price target upped by Canaccord Genuity Group from $12.00 to $20.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently weighed in on IVA. Stifel Nicolaus dropped their target price on Inventiva from $27.00 to $25.00 and set a buy rating on the stock in a report on Friday, February 16th. Lifesci Capital reiterated an outperform rating on shares of Inventiva in a report on Friday, January 5th. Finally, HC Wainwright reiterated a buy rating and issued a $22.00 target price on shares of Inventiva in a report on Monday, April 1st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of Buy and an average price target of $17.00.

Inventiva Stock Up 2.1 %

IVA stock opened at $3.86 on Monday. Inventiva has a one year low of $2.22 and a one year high of $5.05. The firm has a 50-day moving average of $3.71 and a two-hundred day moving average of $3.97.

Institutional Investors Weigh In On Inventiva

A number of large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its position in Inventiva by 20.5% during the third quarter. Commonwealth Equity Services LLC now owns 24,435 shares of the company’s stock worth $103,000 after purchasing an additional 4,155 shares during the period. Citigroup Inc. boosted its position in Inventiva by 91.7% during the first quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock worth $84,000 after purchasing an additional 11,000 shares during the period. Finally, Morgan Stanley boosted its position in Inventiva by 300.0% during the fourth quarter. Morgan Stanley now owns 6,000 shares of the company’s stock worth $27,000 after purchasing an additional 4,500 shares during the period. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.